Help Everyone Live a Healthy Life.


Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines.


Headquartered in China’s southwestern city Kunming, Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines.


With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, Walvax produces efficacious, quality, innovative and affordable products to protect people from the world’s deadliest diseases, for the purpose of helping everyone live a healthy life.

Walvax has assembled a seasoned core management team consisting of entrepreneurial teams from CNBG and senior vaccine experts from MNCs, as well as 10 senior overseas returnee scientists and over 100 doctor's or master's degree personnel.


Walvax has established 4 advanced platforms for the research and development of polysaccharide and conjugate vaccines, recombinant protein and VLP vaccines, adenovirus vector vaccines, and mRNA vaccines. With COVID-19 pandemic raging globally, Walvax has led the efforts in developing 3 vaccinology for SARS-CoV-2 virus, which are, mRNA vaccinology, adenoviral vector based vaccinology and recombinant subunit vaccinology. Meanwhile, Walvax has successfully developed 8 licensed vaccines (12 presentations), including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV-2).

Till date, Walvax has three manufacturing centers in Yuxi City, Yunnan, Daxing District, Beijing and Taizhou City, Jiangsu, respectively. Located in Yuxi City which is about 40 miles (70 km) south of Kunming, Walvax's commercial manufacturing facility of 93,000 m² plant space is currently manufacturing all licensed and to be licensed vaccines. The annual capacity for a variety of vaccines at Yuxi facility is about 190 million doses a year.


Walvax covers 2,400 counties (2,846 in total) among 31 provinces (31 in total) in China. As of today, Walvax manufactures and distributes PCV13, HPV-2, Haemophilus influenza type b conjugate vaccine, Group A and C meningococcal polysaccharide vaccine (MPV AC), Group A and group C meningococcal conjugate vaccine (MCV AC), Group ACYW135 meningococcal polysaccharide vaccine (MPV ACYW135), 23-valent pneumococcal polysaccharide (PPSV23) and Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (DTaP) in China. Beyond China, Walvax has worked closely with business partners to reach overseas markets on the Belt and Road, and has been exporting vaccines to 17 countries, including the United States, Egypt, Indonesia, the Philippines, Bangladesh, Guinea, Nigeria, Senegal, Mauritius, Niger, India, Kyrgyzstan, etc.

In the global collaboration area, Walvax and its subsidiaries have been partnering with academic institutions, industry peers and international organizations. Hitherto, Walvax has received three grants worth US$ 8.5 million in total from the Bill & Melinda Gates Foundation to support WHO prequalification for the HPV-2 and HPV-9 in order to prepare for UNICEF procurement for Gavi countries, and to expedite pre-clinical research of Recombinant Subunit SARS-CoV-2 Vaccine as well. Walvax has also partnered with CEPI and expanded collaboration to develop COVID-19 multi-variant vaccine, with a total of US$ 25.1 million grant being received. In addition, HPV-2, MPV ACYW135 and MCV AC are under WHO-PQ assessment, while PCV13 is undergoing WHO-PQ dossier preparations.

Performance Innovation Marketing


USD541.1 million revenue in 2021


17.8% increase in revenue since 2020


8 new vaccines and 1 siRNA therapeutics under development


68 authorized invention patents at home and abroad


10+ patents application in progress


cities covered in China


Products exported to 18 countries


countries registration in progress


Engaged 80+ partners in 5 continents

Our Journey

Over the past two decades, Walvax has achieved many milestones in developing vaccines.

Learn More



The growth of Walvax is strongly supported by the advancement on developing vaccines.

National-recognized Enterprise Technology Center

Issued by National Development and Reform Commission (NDRC), Ministry of Science and Technology (MOST), Ministry of Finance, The General Administration of Customs (GACC), and State Administration of Taxation (SAT)

National High-tech Industrialization Demonstration Project

Issued by National Development and Reform Commission (NDRC)

High and New Technology Enterprise

Issued by Yunnan Provincial Science and Technology Department, Yunnan Provincial Finance Department, Yunnan Provincial State Taxation Bureau, and Yunnan Provincial Local Taxation Bureau

International Science & Technology Cooperation Base

Issued by Department of International Cooperation, Ministry of Science & Technology of China

Find Out More


Learn about our marketed products.


Learn about our industry-leading manufacturing capacity.


Learn about our reliable and effective distribution capacity.